ABL1 and Parkinson disease: Other pharmacological approaches aim to block c-Abl, a kinase involved in the later stages of the autophagy pathway, by modulating lysosomal maturation through enzymes such as cathepsin D and cathepsin L. The c-Abl modulator, Nilotinib, showed favorable tolerability and safety but no improvement in the motor outcome of PD patients[86].